An interventional study of Spontaneous Ventilation Strategy and Controlled Ventilation Strategy in Acute Respiratory Distress Syndrome (ARDS) and Acute Hypoxemic Respiratory Failure, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Acute hypoxemic respiratory failure may progress to acute respiratory distress syndrome, a life-threatening condition that often requires mechanical ventilation. The optimal ventilation strategy in this patient population remains uncertain.
The SVALBARD trial is a feasibility and pilot study designed to compare spontaneous versus controlled mechanical ventilation in patients with acute hypoxemia respiratory failure.
The primary objective is to assess the feasibility of the study procedures and interventions, while also collecting descriptive data on key clinical variables to inform the design of a future randomized controlled trial.
Acute hypoxemic respiratory failure is a condition that can progress to acute respiratory distress syndrome (ARDS), requiring invasive mechanical ventilation to support gas exchange and limit lung injury. ARDS guidelines recommend lung-protective ventilation strategies-specifically low tidal volumes and limited airway pressures-to reduce ventilator-induced lung injury. Observational studies, including the global LUNG SAFE project, have described the epidemiology and management of acute hypoxemic respiratory failure and ARDS. These studies report high mortality rates (global hospital mortality, 38.6%) associated with the severity of lung injury rather than strict fulfilment of ARDS criteria. They also reveal variability in the application of evidence-based ventilation strategies across institutions. This inconsistency highlights a barrier to progress: the lack of conclusive evidence guiding ventilation management in patients with acute hypoxemic respiratory failure.
One unresolved issue is the role of spontaneous breathing during mechanical ventilation. Observational studies suggest that allowing spontaneous effort may reduce need for sedation and increase ventilator-free days. In contrast, preclinical models indicate that spontaneous breathing in severe lung injury may worsen outcomes through mechanisms such as patient-ventilator asynchrony and regional overdistension. This contrast underscores the need to balance potential benefits against physiological risks in the absence of adequate trial data. ARDS guidelines do not provide clear recommendations on this issue due to limited evidence. Only one large RCT has compared controlled ventilation to spontaneous breathing modes, finding no difference in short-term outcomes and not assessing long-term endpoints such as cognitive impairment or quality of life.As a result, clinicians must choose between guideline-based controlled ventilation and approaches that incorporate spontaneous breathing, within the context of evolving sedation practices and recovery goals. Given the variability of acute hypoxemic respiratory failure and the current evidence gap, genuine uncertainty ('clinical equipoise') exists regarding the optimal ventilation strategy. This supports the need for well-designed RCTs to determine whether spontaneous ventilation offers clinical benefit or harm. A recent survey of Nordic clinicians showed support for such a trial in patients with moderately severe acute hypoxemic respiratory failure, underscoring the relevance of this research.
The SVALBARD study is a feasibility and pilot trial comparing spontaneous and controlled mechanical ventilation in patients with acute hypoxemic respiratory failure. The study will evaluate whether it is possible to recruit patients, apply the assigned ventilation strategies, and collect the required data in a reliable way.
In addition, the study will collect descriptive clinical data to better understand patient characteristics and outcomes. The results will be used to improve the design and planning of a future randomized controlled trial.
The trial will accrue 80 patients from eight different intensive care units, four in Norway and four in Denmark.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
This study's planned enrollment of 80 is above the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Browse Respiratory Distress Syndrome studies →Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
We will include patients who fulfil all the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Invasive mechanical ventilation in which the patient initiates some or all breaths, and the ventilator assists or supports those spontaneous efforts.
Procedure: Spontaneous Ventilation Strategy
Invasive mechanical ventilation in which all breaths are delivered by the ventilator, with no patient-initiated respiratory effort.
Procedure: Controlled Ventilation Strategy
Invasive mechanical ventilation strategy allowing spontaneous breathing while receiving ventilatory support from a standard ICU mechanical ventilator.
Invasive mechanical ventilation strategy in which spontaneous respiratory effort is suppressed and breaths are fully delivered by a standard ICU mechanical ventilator.
Recruitment Rate
Proportion of eligible patients who are enrolled in the trial (primary feasibility outcome).
Time frame: 1 year from trial initiation
Consent Rate
Proportion of eligible patients who provide informed consent to participate in the trial.
Time frame: 1 year from trial initiation
Randomisation Rate
Proportion of consented participants who are randomised.
Time frame: 1 year from trial initiation
Protocol Adherence
Proportion of study procedures completed according to protocol requirements.
Time frame: 1 year from trial initiation
Major Protocol Violations
Proportion of enrolled participants with at least one major protocol deviation.
Time frame: 1 year from trial initiation
Retention Rate
Proportion of randomised participants who complete study follow-up.
Time frame: 1 year from trial initiation
Time to Completion of Feasibility Study
Time from trial initiation to completion of feasibility study recruitment and follow-up.
Time frame: Up to 1 year
Proportion of Participants Achieving Therapeutic Target at 48 Hours
Proportion of randomised participants achieving the predefined therapeutic target within 48 hours after randomisation.
Time frame: 48 hours from randomisation
Between-Group Difference in Therapeutic Target Attainment at 48 Hours
Difference between study groups in the proportion of participants achieving the predefined therapeutic target at 48 hours.
Time frame: 48 hours
Proportion of Missing Therapeutic Target Data at 48 Hours
Proportion of randomised participants with missing data for the predefined therapeutic target assessed 48 hours after randomisation.
Time frame: 48 hours from randomisation
Clinical: All-Cause Mortality at 30 Days
Proportion of enrolled participants who have died from any cause by 30 days.
Time frame: 30 days
Clinical: All-Cause Mortality at 90 Days
Proportion of enrolled participants who have died from any cause by 90 days.
Time frame: 90 days
Clinical: All-Cause Mortality at 180 Days
Proportion of enrolled participants who have died from any cause by 180 days.
Time frame: 180 days
Clinical: Clinical: Days Alive and Free of Life Support at 90 Days
Number of days alive and free of life support (invasive mechanical ventilation, renal replacement therapy, or vasoactive drug support) from randomisation through day 90. Life support-free days are calculated as the number of calendar days alive and free of all listed life support modalities during the 90-day period. Participants who die before day 90 will be assigned 0 days.
Time frame: 90 days
Clinical: Days Alive and Out of Hospital at 90 Days
Number of days alive and out of hospital from randomisation through day 90. Participants who die before day 90 will be assigned 0 days.
Time frame: 90 days
Clinical: Health-related quality of life (EQ-5D-5L Index Score)
Health-related quality of life measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) index score. The index value ranges from less than 0 (health state worse than death) to 1 (best health), with higher scores indicating better health. Participants who die before assessment will be assigned a value of 0.
Time frame: 180 days
Clinical: Health-Related Quality of Life (EQ-5D Visual Analogue Scale Score)
Health-related quality of life measured using the EQ-5D Visual Analogue Scale (VAS), ranging from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better health. Participants who die before assessment will be assigned a value of 0.
Time frame: 180 days
Clinical: Montreal Cognitive Assessment (MoCA) Score at 180 Days
Cognitive function assessed using the Montreal Cognitive Assessment (MoCA) Version 2.1 (telephone version). Scores range from 0 to 15, with higher scores indicating better cognitive function. Participants who die before assessment will be assigned a score of 0.
Time frame: 180 days
Clinical: Impact of Event Scale-6 (IES-6) Score at 180 Days
Post-traumatic stress symptoms assessed using the Impact of Event Scale-6 (IES-6). The scale consists of six items rated from 0 (not at all) to 4 (extremely). The mean score ranges from 0 to 4, with higher scores indicating more severe post-traumatic stress symptoms.
Time frame: 180 days
Clinical: Modified Medical Research Council (mMRC) Dyspnea Scale Score at 180 Days
Dyspnea assessed using the Modified Medical Research Council (mMRC) Dyspnea Scale. Scores range from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house or while dressing/undressing), with higher scores indicating worse dyspnea.
Time frame: 180 days
Clinical: Chalder Fatigue Questionnaire (CFQ) Score at 180 Days
Fatigue assessed using the Chalder Fatigue Questionnaire (CFQ), consisting of 11 items scored from 0 to 3. Total scores range from 0 to 33, with higher scores indicating greater fatigue.
Time frame: 180 days
Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 12 months is below that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →